JP2010518029A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010518029A5 JP2010518029A5 JP2009548551A JP2009548551A JP2010518029A5 JP 2010518029 A5 JP2010518029 A5 JP 2010518029A5 JP 2009548551 A JP2009548551 A JP 2009548551A JP 2009548551 A JP2009548551 A JP 2009548551A JP 2010518029 A5 JP2010518029 A5 JP 2010518029A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic agent
- alkyl
- acyl
- plasmenyl
- glycerol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 46
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims 44
- 229940124597 therapeutic agent Drugs 0.000 claims 44
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 34
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims 20
- 208000010877 cognitive disease Diseases 0.000 claims 20
- 208000028698 Cognitive impairment Diseases 0.000 claims 19
- 235000012000 cholesterol Nutrition 0.000 claims 17
- 235000014113 dietary fatty acids Nutrition 0.000 claims 17
- 229930195729 fatty acid Natural products 0.000 claims 17
- 239000000194 fatty acid Substances 0.000 claims 17
- 150000004665 fatty acids Chemical class 0.000 claims 17
- 230000000069 prophylactic effect Effects 0.000 claims 10
- GNGACRATGGDKBX-UHFFFAOYSA-N dihydroxyacetone phosphate Chemical compound OCC(=O)COP(O)(O)=O GNGACRATGGDKBX-UHFFFAOYSA-N 0.000 claims 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 8
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims 8
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims 8
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 230000003449 preventive effect Effects 0.000 claims 5
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 claims 4
- SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical class NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 claims 4
- 229910019142 PO4 Inorganic materials 0.000 claims 4
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 4
- 229960000541 cetyl alcohol Drugs 0.000 claims 4
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims 4
- 229940055577 oleyl alcohol Drugs 0.000 claims 4
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 claims 4
- KLAKIAVEMQMVBT-UHFFFAOYSA-N p-hydroxy-phenacyl alcohol Natural products OCC(=O)C1=CC=C(O)C=C1 KLAKIAVEMQMVBT-UHFFFAOYSA-N 0.000 claims 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical class [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 4
- 239000010452 phosphate Chemical class 0.000 claims 4
- 229940012831 stearyl alcohol Drugs 0.000 claims 4
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 claims 4
- 125000002252 acyl group Chemical group 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 229940126033 PPAR agonist Drugs 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 150000001982 diacylglycerols Chemical class 0.000 claims 2
- 238000004949 mass spectrometry Methods 0.000 claims 2
- 230000003557 neuropsychological effect Effects 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 101100424823 Arabidopsis thaliana TDT gene Proteins 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 230000001149 cognitive effect Effects 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000011156 evaluation Methods 0.000 claims 1
- 150000004668 long chain fatty acids Chemical class 0.000 claims 1
- 230000006996 mental state Effects 0.000 claims 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88888307P | 2007-02-08 | 2007-02-08 | |
| US60/888,883 | 2007-02-08 | ||
| PCT/CA2007/001472 WO2008095275A1 (en) | 2007-02-08 | 2007-08-27 | Methods for the treatment of senile dementia of the alzheimer's type |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010518029A JP2010518029A (ja) | 2010-05-27 |
| JP2010518029A5 true JP2010518029A5 (enExample) | 2010-10-21 |
| JP5470050B2 JP5470050B2 (ja) | 2014-04-16 |
Family
ID=39537686
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009548551A Active JP5470050B2 (ja) | 2007-02-08 | 2007-08-27 | アルツハイマー型老年認知症の治療方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (5) | US9034923B2 (enExample) |
| EP (2) | EP2620147B1 (enExample) |
| JP (1) | JP5470050B2 (enExample) |
| AU (1) | AU2007346587C1 (enExample) |
| CA (2) | CA2695167C (enExample) |
| IL (1) | IL200029A0 (enExample) |
| SG (1) | SG173418A1 (enExample) |
| WO (1) | WO2008095275A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007346587C1 (en) | 2007-02-08 | 2015-01-22 | Med-Life Discoveries Lp | Methods for the treatment of Senile Dementia of the Alzheimer's Type |
| TWI475989B (zh) * | 2008-12-22 | 2015-03-11 | Phenomenome Discoveries Inc | 縮醛磷脂類化合物，含彼之醫藥組成物以及治療老化疾病的方法 |
| SG10201405975VA (en) | 2009-10-01 | 2014-11-27 | Phenomenome Discoveries Inc | Serum-based biomarkers of pancreatic cancer and uses thereof for diseasedetection and diagnosis |
| EP3684463B1 (en) | 2017-09-19 | 2025-05-14 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement |
| US11717686B2 (en) | 2017-12-04 | 2023-08-08 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to facilitate learning and performance |
| US11318277B2 (en) | 2017-12-31 | 2022-05-03 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to enhance emotional response |
| US12280219B2 (en) | 2017-12-31 | 2025-04-22 | NeuroLight, Inc. | Method and apparatus for neuroenhancement to enhance emotional response |
| US11364361B2 (en) | 2018-04-20 | 2022-06-21 | Neuroenhancement Lab, LLC | System and method for inducing sleep by transplanting mental states |
| US11452839B2 (en) | 2018-09-14 | 2022-09-27 | Neuroenhancement Lab, LLC | System and method of improving sleep |
| US11786694B2 (en) | 2019-05-24 | 2023-10-17 | NeuroLight, Inc. | Device, method, and app for facilitating sleep |
| CN114236019B (zh) * | 2022-02-24 | 2022-05-06 | 宝枫生物科技（北京）有限公司 | 脑白质病变的生物标志物的应用 |
| JPWO2025057966A1 (enExample) * | 2023-09-12 | 2025-03-20 | ||
| CN118512461A (zh) * | 2024-06-03 | 2024-08-20 | 东莞市第八人民医院（东莞市儿童医院） | 一种母乳来源磷脂在防治支气管肺发育不良的应用 |
| CN119876292B (zh) * | 2025-03-27 | 2025-06-03 | 浙江省白马湖实验室有限公司 | 一种酰胺类缩醛磷脂化合物的制备方法及应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994009371A1 (en) | 1992-10-09 | 1994-04-28 | Massachusetts Institute Of Technology | Antemortem diagnostic test for alzheimer's disease |
| FR2736265B1 (fr) | 1995-07-07 | 1997-09-26 | Forgeot Marcel | Nouvelles compositions a base de phosphoglycero ethers et leur utilisation dans le traitement des maladies neuro-degeneratives |
| US5731354A (en) | 1996-05-06 | 1998-03-24 | Clarion Pharmaceuticals Inc. | Treatment for the inhibition of neuro-degenerative disease states |
| US6177476B1 (en) | 1998-08-27 | 2001-01-23 | Clarion Pharmaceuticals Inc. | Nutritional supplements for replenishing plasmalogens |
| CA2298181C (en) | 2000-02-02 | 2006-09-19 | Dayan Burke Goodnough | Non-targeted complex sample analysis |
| WO2001078652A2 (en) | 2000-04-14 | 2001-10-25 | Metabolon, Inc. | Methods for drug discovery, disease treatment, and diagnosis using metabolomics |
| US6835750B1 (en) | 2000-05-01 | 2004-12-28 | Accera, Inc. | Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II |
| EP1317765A2 (en) | 2000-09-08 | 2003-06-11 | Oxford GlycoSciences (UK) Limited | Automated identification of peptides |
| US6838452B2 (en) * | 2000-11-24 | 2005-01-04 | Vascular Biogenics Ltd. | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
| CA2446886A1 (en) | 2001-04-06 | 2002-10-17 | Biovision Ag | Method for detecting chronic dementia diseases, and corresponding peptides and detection reagents |
| US7202044B2 (en) | 2001-05-09 | 2007-04-10 | Biovision Ag | Method for detecting a progressive, chronic dementia disease, and corresponding peptides and detection agents |
| NZ534751A (en) | 2002-03-22 | 2007-05-31 | Phenomenome Discoveries Inc | Method of visualizing non-targeted metabolomic data generated from fourier transform ion cyclotron resonance mass spectrometers |
| JP2004026803A (ja) * | 2002-03-29 | 2004-01-29 | Nof Corp | 神経細胞死予防剤 |
| CA2745724C (en) | 2002-08-23 | 2015-06-02 | Bayer Schering Pharma Aktiengesellschaft | Biomarkers comprising peptide sequence vnhvtlsqpk for diagnosing alzheimer's disease |
| SE0203886D0 (sv) * | 2002-12-27 | 2002-12-27 | Ltp Lipid Technologies Provide | Glycerolesterprodukt och dess användning |
| US20040191294A1 (en) * | 2003-03-27 | 2004-09-30 | Ramaprasad Talahalli Ravichandra | Health composition |
| EP1637161A4 (en) * | 2003-04-22 | 2007-06-27 | Astellas Pharma Inc | MEANS FOR THE TREATMENT OF NEURODEGENERATIVE ILLNESSES OF THE BRAIN WITH PPAR [delta] AGONIST |
| US7794948B2 (en) | 2003-11-07 | 2010-09-14 | Vermilllion, Inc. | Biomarkers for alzheimer's disease |
| WO2005085838A2 (en) | 2004-03-02 | 2005-09-15 | Vanderbilt University | Computational analysis of mass spectroscopic lipid data |
| WO2005116659A2 (en) | 2004-05-18 | 2005-12-08 | Neurodx, Llc | Compositions and methods relating to alzheimer’s disease |
| WO2007002285A2 (en) * | 2005-06-21 | 2007-01-04 | The Trustees Of The University Of Pennsylvania | Methods for treating neurological and psychiatric conditions |
| JP4176749B2 (ja) | 2005-07-29 | 2008-11-05 | 学校法人帝京大学 | 疾病検査法 |
| SG165370A1 (en) | 2005-09-12 | 2010-10-28 | Phenomenome Discoveries Inc | Method for the diagnosis of colorectal cancer and ovarian cancer by the measurement of vitamin e-related metabolites |
| CA2621126C (en) | 2005-09-15 | 2011-04-12 | Phenomenome Discoveries Inc. | Method and apparatus for fourier transform ion cyclotron resonance mass spectrometry |
| NZ570413A (en) | 2006-02-28 | 2011-07-29 | Phenomenome Discoveries Inc | Methods for the diagnosis of dementia and other neurological disorders |
| SG171691A1 (en) | 2006-05-26 | 2011-06-29 | Phenomenome Discoveries Inc | Biomarkers for diagnosing multiple sclerosis, and methods thereof |
| WO2008093709A1 (ja) * | 2007-01-30 | 2008-08-07 | Tohoku University | アミロイド蛋白質の凝集抑制および分解促進によりアミロイドーシスと関連する疾患を予防または治療するための組成物 |
| AU2007346587C1 (en) | 2007-02-08 | 2015-01-22 | Med-Life Discoveries Lp | Methods for the treatment of Senile Dementia of the Alzheimer's Type |
| US8026099B2 (en) | 2007-07-26 | 2011-09-27 | Washington University | Lipid profile as a biomarker for early detection of neurological disorders |
-
2007
- 2007-08-27 AU AU2007346587A patent/AU2007346587C1/en active Active
- 2007-08-27 CA CA2695167A patent/CA2695167C/en active Active
- 2007-08-27 EP EP13160192.4A patent/EP2620147B1/en active Active
- 2007-08-27 EP EP07800499.1A patent/EP2117527B1/en active Active
- 2007-08-27 CA CA2620274A patent/CA2620274C/en active Active
- 2007-08-27 SG SG2011053717A patent/SG173418A1/en unknown
- 2007-08-27 US US12/090,342 patent/US9034923B2/en active Active
- 2007-08-27 WO PCT/CA2007/001472 patent/WO2008095275A1/en not_active Ceased
- 2007-08-27 JP JP2009548551A patent/JP5470050B2/ja active Active
-
2009
- 2009-07-23 IL IL200029A patent/IL200029A0/en unknown
-
2012
- 2012-06-18 US US13/526,197 patent/US8993623B2/en active Active
-
2015
- 2015-03-19 US US14/663,440 patent/US20160015673A1/en not_active Abandoned
- 2015-03-31 US US14/674,705 patent/US9517222B2/en active Active
-
2016
- 2016-11-11 US US15/349,831 patent/US10123989B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7080944B2 (ja) | 細胞生存率を向上させるための組成物およびその使用方法 | |
| JP6986022B2 (ja) | Ｆｘｒアゴニストを使用するための方法 | |
| CA2620274A1 (en) | Methods for the treatment of senile dementia of the alzheimer's type | |
| JP2012529451A5 (enExample) | ||
| JP6731915B2 (ja) | 多発性硬化症治療用のシポニモドとラキニモドを含む組み合わせ | |
| Yorek | The potential role of fatty acids in treating diabetic neuropathy | |
| JP2023169413A (ja) | 精神病性障害を治療するための方法および組成物 | |
| CA2534202A1 (en) | Lipid glycerides for the treatment of neurodegenerative conditions involving demyelination | |
| JP2016504401A (ja) | 激痛治療用組成物と方法 | |
| IL324298A (en) | Use of nor-ursodeoxycholic acid for reducing liver fat | |
| JP2007520488A5 (enExample) | ||
| JP5043677B2 (ja) | アルツハイマー型認知症予防・治療剤 | |
| CN104352488B (zh) | 一类取代杂环衍生物在制备治疗疼痛药物中的应用 | |
| WO2014129513A1 (ja) | 潰瘍性大腸炎の予防または治療剤と新規フラーレン誘導体 | |
| JP6650006B2 (ja) | 脂質異常症治療剤 | |
| JP6422890B2 (ja) | フェノキシプロピルアミン化合物を使用してうつ病を治療する方法 | |
| JP2019523288A (ja) | 非アルコール性脂肪性肝炎及び繊維症のための新規治療 | |
| JP7257091B2 (ja) | 認知症の治療及び予防薬 | |
| CN104053441B (zh) | 用于预防或治疗高脂血症的药物组合物 | |
| JPWO2004000301A1 (ja) | ジアシルグリセリルエーテルを含有する経口用皮膚損傷予防・治療剤 | |
| JP2012102069A (ja) | 早漏治療剤 | |
| JP3213760B2 (ja) | 痴呆疾患の治療または予防の為の組成物と、それを処方物にした抗痴呆薬 | |
| AU2017266729A1 (en) | Carboxylic acids for early childhood application | |
| US20090137632A1 (en) | Compositions And Methods For Treating Dyslipidemia | |
| WO2020240489A1 (en) | Selective histamine h3 receptor antagonists for treating autism spectrum disorder |